Actavis, a global speciality pharmaceutical company, has acquired Silom Medical Company, a privately held generic pharma company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. The acquisition of Silom Medical immediately elevates Actavis into a top-five position in the Thai generic pharma market, with leading positions in the ophthalmic and respiratory therapeutic categories and a strong cardiovascular franchise. The transaction is expected to be immediately accretive to non-GAAP earnings in 2014.
“The acquisition of Silom Medical demonstrates our commitment to be a leading speciality pharma company in Southeast Asia, and will provide the combined business with an even more significant and united presence in the fast-growing Thai pharma market,” said Paul Bisaro, Chairman and Chief Executive Officer, Actavis.
“Silom Medical’s diverse product portfolio and fully integrated platform, when combined with Actavis’ current local commercial activities and world-class global generics infrastructure, will provide consumers in Thailand with expanded access to a combined, larger portfolio of affordable medicines and the increased opportunity to benefit from products in development for the market,” said Bisaro. Actavis markets approximately a dozen products through local distributors in Thailand, and has approximately nine additional products under registration. The combination is anticipated to result in opportunities to expand the core therapeutic areas of cardiovascular, ophthalmology and respiratory with complementary and novel products, as well as the potential to use Silom Medical’s sales channels to create opportunities in new therapeutic categories including oncology, women’s health, CNS and others. Silom Medical offers more than 25 products in various dosage forms to more than 4,400 hospitals, clinics and drug stores throughout the country. The company has an in-house sales force and operates a 32,000 sq mt manufacturing facility in Ayutthaya with a production capacity of 660 million tablets/capsules and 47 million sterile units per year.
EP News Bureau – Mumbai